灭幽灵治疗消化性溃疡伴幽门螺旋杆菌阳性(郁热证)80例临床疗效观察

灭幽灵散剂治疗消化性溃疡活动期伴幽门螺杆菌阳性、辨证为郁热证８０例（治疗组）．并与用得乐冲剂治疗的２８例作对照（对照组），６周为１疗程。结果：中医证候疗效比较，治疗组治愈＋显效率８５．０％，总有效率９３．８％；对照组治愈＋显效率６６．９％，总有效率８２．１％。溃疡疗效比较：治疗组治愈＋显效率８０．０％，总有效率８７．５％；对照组治愈＋显效率６０．７％，总有效率７５．０％。两组比较有显著性差异（Ｐ＜０．０５）。幽门螺旋杆菌疗效比较：治疗组清除率７１．２％，对照组６７．９％，两组比较无显著性差异（Ｐ＞０．０５）。说明灭幽灵散剂对改善症状、愈合溃疡疗效明显优于得乐冲剂。远期疗效；治疗组溃疡复发率２１．０％，对照组为２３．０％。幽门螺杆菌两项检查复发率两组分别为２８．５％、３０．８％，相比较无显著性差异（Ｐ＞０．０５）。此结果说明溃疡复发与幽门螺杆菌密切相关。     

脾栓塞治疗免疫性血小板减少性紫癜

２１例慢性免疫性血小板减少性紫癜（ＩＴＰ）和２例ＥＶＡＮＳ综合征患者接受部分脾动脉栓塞治疗。结果：显效１４例，占６０．９％，良效５例，占２１．７％，总有效率８６．６％。术后观察１年以上者８例，５例仍为显效，３例（３７．５％）复发，２例经强的松等治疗再获良效，１例无效。对照组：２５例ＩＴＰ患者作切脾治疗。显效１７例（６８．０％），良效５例（２０．０％），无效３例（１２．０％）总有效率８８．０％。两组比较（Ｐ＞０．０５）差异无显著性。     

月见草油治疗十二指肠溃疡的研究

目的研究月见草油对十二指肠溃疡（ＤＵ）的治疗作用．方法选经内镜确诊为ＤＵ的住院患者１２０例，随机分为治疗组（ｎ＝６０）和对照组（ｎ＝６０）．治疗组服用月见草油１５ｇ，４次／ｄ，对照组服用西味替丁２００ｍｇ，４次／ｄ，两组均为４周１疗程．治疗前及治疗４周后各做胃镜１次，观察溃疡的愈合情况，同时，治疗前及治疗４周后用放免法分别测定血浆内的ＰＧＥ２含量．结果治疗组与对照组患者的消化道症状均较服药前明显减轻（Ｐ＜００１），两组间无显著性差异（Ｐ＞００５）．４周溃疡愈合率和有效率，治疗组为７６６％和８６６％，对照组分别为７００％和８３３％，两组间无显著性差异（Ｐ＞００５），对照组于治疗前后血浆ＰＧＥ２水平无显著性差异，而治疗组于治疗前后的血浆ＰＧＥ２水平却有显著性差异（９４５ｎｇ／Ｌ±３７ｎｇ／Ｌ→１７２３ｎｇ／Ｌ±５７ｎｇ／Ｌ，Ｐ＜００５）．结论月见草对ＤＵ的近期疗效较好，可用于治疗ＤＵ．     

核素心脏显像评估心肌缺血预适应对老年人心肌梗死面积和心功能的影响

目的通过核素心脏显像评估心肌缺血预适应对老年人首发急性心肌梗死（急性心梗，ＡＭＩ）面积和心功能的影响。方法５３例首发急性心梗患者，根据心梗前２４小时有无心绞痛发作分为心绞痛组及无心绞痛组，均在急性心梗后２～４周行核素心脏显像。对比研究心梗的面积和心功能状况。结果心绞痛组和无心绞痛组心梗节段数分别是（３．２±２．６）段和（５．６±２．６）段，两组比较，差异有显著性（Ｐ＜０．０１）；左室扩大和反向运动的发生率分别为１２．０％（３例）和３９．３％（１１例）（Ｐ＜０．０５）；左室射血分数分别是（４９．３±８．６）％和（４１．８±１１．４）％（Ｐ＜０．０１）；高峰充盈率分别是（２．１±０．４）ｅｄｃ／ｓ和（１．６±０．６）ｅｄｃ／ｓ（Ｐ＜０．０１）。结论老年人ＡＭＩ前短期内心绞痛发作能缩小梗死面积，对左室功能有积极保护作用。     

兰索拉唑治疗十二指肠溃疡的临床观察

为验证第二代质子泵抑制剂兰索拉吐治疗十二指肠溃疡的疗效，对经胃镜检查诊断的治疗活动期十二指肠溃疡患者３８例作了观察，并与奥美拉唑组３４例进行了对照。结果两组十二指肠溃疡４周的愈合率分别为９７．４％和９１．２％，有效率分别为１００％与９７．１％（Ｐ＞０．０５）；疼痛消失率两组分别为１００％和９３．５％（Ｐ＞０．０５），而３天内疼痛消失率分别为７４．３％和５１．６％（Ｐ＜０．０５）。兰索拉唑治疗过程中未发现有副作用。提示兰索拉唑是治疗十二指肠溃疡有效的和安全的药物。     

替普瑞酮对胃溃疡愈合及其愈合质量的影响

为了研究替普瑞酮对胃溃疡的治疗效果，对１０６例经胃镜证实的胃溃疡病人，随机分为Ａ组（替普瑞酮＋西咪替丁）和Ｂ组（单用西咪替丁）。４周溃疡愈合率Ａ、Ｂ两组分别为７２．４％和５２．１％（Ｐ＜０．０５），８周为９３．１％和８９．６％（Ｐ＞０．０５）；Ｓ２期的获得率４周分别为３４．５％和１０．４％，８周为５０．０％和２０．８％（Ｐ＜０．００５）。氨基己糖测定：Ａ组治疗后（１７．７９±２．００μｇ／ｍｇ）明显高于治疗前（１４．２７±２．４７μｇ／ｍｇ）（Ｐ＜０．０５），而Ｂ组治疗前后则无明显变化。本研究结果强烈提示Ａ组加用替普瑞酮不仅加速了胃溃疡的愈合，而且显示溃疡愈合质量亦明显高于单用西咪替丁组，这可能与替普瑞酮显著增加氨基己糖含量有关     

蝮蛇抗栓酶与肝素治疗肺心病急性加重期的疗效比较

对１３５例肺心病急性加重期住院患者随机分为三组：蝮蛇抗栓酶治疗组，肝素治疗组，常规治疗组（对照组），结果总有效率分别为８２．２％，７３．３％，５７．８％。三组间疗效差异有显著性（Ｐ＜０．００５）。就治疗机理及不良反应作简要讨论。     

卡托普利治疗对急性心肌梗塞二级预防的作用

８２２例首次急性心肌梗塞症状后７２小时内入院且无心源性休克患者中，４７８例自入院后开始并于随访期持续接受常规及卡托普利治疗（甲组），３４４例单纯接受常规治疗（乙组）。住院期间中，甲组病死率（６．９％）明显低于乙组（１８％）（Ｐ＝０．００１），且心肌梗塞前壁或（和）下壁具相似作用（前壁：６．８％和１８．３％，Ｐ＜０．００１；下壁：６．４％和１３．５％，Ｐ＜０．０５；前壁＋下壁：１０．７％和３９．２％，Ｐ＜０．０３）。随访期（平均２０个月）中，尽管两组再梗塞和严重心律失常发生率相似，但甲组的病死率（２．３％和１６．２％，Ｐ＝０．０３２４）和总心脏性事件发生率（１０．３％和３７．４％，Ｐ＝０．０５５）显著低于乙组。因此，急性心肌梗塞后早期并持续应用血管紧张素转换酶抑制剂－卡托普利治疗对患者的预后具有益作用。     

胺碘酮、普罗帕酮对QTc离散度的影响比较及其临床意义

目的比较胺碘酮（２７例）和普罗帕酮（３４例）分别治疗室性心律失常前后ＱＴｃ离散度（ＱＴｃｄ）的变化及对复发的影响。方法采用随机、单盲的方法，测定两组病人用药前及用药２周后的ＱＴｃｄ。结果（１）胺碘酮组用药后ＱＴｃ明显延长，但ＱＴｃｄ反而降低（４４．３±１４．９ｍｓ与３３．９±１６．１ｍｓ，Ｐ＜０．０５）；普罗帕酮组用药前后ＱＴｃ及ＱＴｃｄ无显著变化（Ｐ均＞０．０５）。（２）胺碘酮组和普罗帕酮组的有效率分别为８５．２％和８２．４％（Ｐ＞０．０５）；停药后１月内的室性心律失常复发率分别为１８．５％和５０％（Ｐ＜０．０５），普罗帕酮组复发者较未复发者的ＱＴｃｄ明显延长（４８．７±１５．３ｍｓ与３９．８±１２．５ｍｓ，Ｐ＜０．０１）。结论ＱＴｃｄ的降低可能是胺碘酮治疗室性心律失常复发率较低的重要因素     

替硝唑治疗阿米巴肝脓肿的疗效观察

目的观察替硝唑对阿米巴肝脓肿的临床疗效。方法以每日顿服替硝唑２．０ｇ，５日疗法治疗３３例阿米巴肝脓肿患者，并与甲硝唑１４日疗法治疗３１例阿米巴肝脓肿患者进行比较。结果替硝唑组患者体温恢复正常时间（３．７±０．５天），平均住院天数（２４．３±１．５天）及总有效率（７８．８％）与甲硝唑组比较，差异无显著性（Ｐ＞０．０５）。但替硝唑组患者脓腔缩小所需时间较短，肝区疼痛消失较早，不良反应亦比甲硝唑组较少（Ｐ＜０．０５）。结论替硝唑是一种治疗阿米巴肝脓肿的新的良好药物     

阿司匹林、噻氯匹啶与低分子肝素联合治疗不稳定型心绞痛疗效观察

目的 :评价在阿司匹林与噻氯匹啶合用基础上使用低分子肝素治疗不稳定型心绞痛疗效及安全性。方法 :不稳定型心绞痛 90例随机分成 3组 ,A组为常规治疗组 ,给予口服阿司匹林 ,每天 10 0 mg;B组为 A组加服噻氯匹啶。每天 2 5 0 m g;C组为在 B组治疗基础上 ,给予皮下注射低分子肝素 ,每次 0 .4 m l（410 0 U AXa WHO单位 ） ,除第 1天 12 h1次外 ,每天 1次。疗程均为 7d。各组均给予硝酸酯类、β受体阻滞剂、钙拮抗剂。结果 :A、B、C3组总有效率分别为 5 7%、6 3%、90 % ,C组总有效率与 A组比较有显著性差异 （P<0 .0 1）。随访 30 d,C组急性心脏事件发生率明显低于 A组 （P<0 .0 5 ） ,与 B组无显著性差异 （P>0 .0 5 ）。不良反应 ,3组间无显著性差异 （P>0 .0 5 ）。结论 :阿司匹林、噻氯匹啶与低分子肝素联合治疗不稳定型心绞痛疗效确切 ,使用安全 ,且能减少急性心脏事件发生率     

辛伐他汀联合低分子肝素治疗不稳定型心绞痛的疗效观察

目的观察辛伐他汀联合低分子肝素治疗不稳定型心绞痛（UA）的疗效。方法选择2008年6月—2010年6月来我院就诊的不稳定心绞痛的患者93例。随机分为治疗组和对照组。对照组给予β受体阻滞剂、硝酸酯类药物、血管紧张素转换酶抑制剂（ACEI）;治疗组在对照组治疗基础上加用辛伐他汀同时给予低分子肝素。结果治疗组总有效率为93.75%,对照组总有效率为66.67%,治疗组总有效率明显高于对照组,差异有统计学意义（P〈0.05）。结论辛伐他汀和低分子肝素联合治疗不稳定型心绞痛疗效显著。     

低分子肝素治疗不稳定型心绞痛临床疗效观察

目的　观察低分子肝素 (吉派啉 )治疗不稳定性心绞痛 (UAP)的临床疗效。方法　 66例UAP患者随机分为常规治疗组 (对照组 )及常规治疗加吉派啉 (治疗组 ) ,疗程为 7天 ,观察用药前后临床症状、心电图、凝血指标及血总胆固醇、甘油三酯、纤维蛋白原的变化。结果　治疗组一周后总有效率为 91.7% ,对照组为 60 .0 % (P <0 .0 1) ;治疗组无一例发生急性心肌梗塞 ,对照组 2例发生 (6.66% ) ;治疗组未发现严重不良反应。血总胆固醇、甘油三酯及纤维蛋白原显著降低 (P <0 .0 1)。疗效明显优于对照组。结论　UAP急性期在常规治疗基础上加用低分子肝素 ,能有效地控制心绞痛发作 ,减少心肌梗塞发生率 ,且安全便利     

血栓通治疗不稳定型心绞痛的临床疗效研究

目的研究血栓通治疗不稳定型心绞痛(UAP)的临床疗效。方法选择2011年3月—2013年3月在延安大学咸阳医院心内科住院治疗的UAP患者60例,随机分为血栓通组和对照组,各30例。对照组予以常规药物治疗,血栓通组在对照组治疗基础上加用血栓通治疗,均观察14 d。比较两组患者治疗前后心绞痛发作频率和持续时间,记录两组患者心电图ST段压低≥0.25 m V的导联总数(NST)和心电图ST段压低的电压总量(∑ST),判定两组患者心绞痛症状疗效和心电图疗效,观察两组患者临床终点事件和不良反应发生情况。结果治疗前两组患者心绞痛发作频率和持续时间比较,差异无统计学意义(P0.05);治疗后血栓通组患者心绞痛发作频率少于对照组〔(1.4±1.3)次∕周比(2.2±1.4)次/周,P0.05〕,持续时间短于对照组〔(3.3±1.8)min/次比(4.3±1.9)min∕次,P0.05〕,心电图NST少于对照组〔(1.14±1.04)个比(1.70±1.06)个,P0.05〕、心电图∑ST低于对照组〔(2.64±1.13)mm比(3.42±1.34)mm,P0.05〕。血栓通组患者心绞痛症状总有效率为90.0%,高于对照组的70.0%(P0.05);血栓通组患者心电图总有效率为86.7%,高于对照组的66.7%(P0.05)。对照组患者临床终点事件发生率为13.3%,与血栓通组的6.7%比较,差异无统计学意义(P0.05)。治疗期间两组患者均未出现过敏反应、严重出血。结论在常规药物治疗基础上应用血栓通治疗UAP安全有效,能进一步改善患者心绞痛症状和心电图表现。     

低分子肝素治疗不稳定型心绞痛临床观察

目的 :观察低分子肝素 (速避凝 )治疗不稳定型心绞痛 ( UAP)的临床疗效。方法 :将 6 4例 U AP患者随机分为常规治疗组 (对照组 )及常规治疗加速避凝组 (治疗组 ) ,疗程为 1周。结果 :1周后总有效率 :治疗组为93.75 % ,对照组为 6 8.75 % ( P <0 .0 5 ) ;观察 12周治疗组无一例发生急性心肌梗死 ,对照组 3例发生 ( 9.38% ) ;治疗组未发现明显不良反应。结论 :在常规治疗基础上加用速避凝 ,能更有效地控制心绞痛发作 ,减少心肌梗死发生率     

血栓通注射液治疗不稳定型心绞痛的有效性及安全性研究

目的探讨血栓通注射液治疗不稳定型心绞痛的有效性和安全性。方法选择我院2011年8月—2013年8月收治的不稳定型心绞痛患者150例,采用随机数字表法分为对照组和观察组,每组75例。对照组患者给予常规治疗,观察组患者在常规治疗基础上加用血栓通注射液,两组患者均连续治疗2周。观察两组患者临床疗效,治疗前后心绞痛发作频率及发作持续时间,治疗期间不良反应情况。结果观察组患者总有效率为90.67%,高于对照组的70.67%(P0.01)。治疗前,两组患者心绞痛发作频率及发作持续时间比较,差异均无统计学意义(P0.05);观察组患者治疗后心绞痛发作频率低于对照组,发作持续时间短于对照组(P0.05)。对照组患者治疗期间不良反应发生率为5.33%,观察组为8.00%,差异无统计学意义(P0.05)。结论血栓通注射液治疗不稳定型心绞痛有效性较好,安全性较高,具有较高的临床价值。     

Clinical factors affecting the immediate outcome of PTCA in patients with unstable angina and poor candidates for surgery

Percutaneous Transluminal Coronary Angioplasty (PTCA) has been successfully applied in unstable angina to carefully selected patients. In this study, PTCA was performed in 277 consecutive patients suffering from unstable angina and for whom bypass surgery was not a valid alternative because either of inoperable conditions or of emergency, or because surgery was not the best option. All patients were admitted first to the intensive care unit where an attempt was made to control unstable angina under conventional medical therapy using at least iv nitroderivative, heparin, and calcium blockers. After a standardized preparation PTCA was performed either as an emergency procedure in medically refractory unstable angina (107 cases) or as an elective procedure in controlled situations after a 7 to 10 days symptom-free period. Three hundred fifty-three coronary vessels were attempted. Results of this group are compared with those of a control group made of 670 consecutive stable patients recruited during the same period, and clinical characteristics are envisaged as potential predictive factors. Unstable angina is undoubtedly associated with a higher overall complication rate, but the immediate outcome is strongly affected by the clinical context. As an example, respective success and mortality rates are: 93% and 0% when a full revascularization is attempted; 91% and 0% in elective procedures in patients under 60; 87% and 1.2% in elective PTCA for multiple vessel disease; 80% and 6.5% in emergency PTCA; 80% and 11% in the overall triple vessel disease; 84% and 16% in patients with deeply altered ejection fraction; and 58% and 26% in triple vessel disease with 2 previously occluded coronary arteries.(ABSTRACT TRUNCATED AT 250 WORDS)     

Randomized trial of thrombolysis versus heparin in unstable angina.

BACKGROUND. The clinical usefulness of intravenous thrombolytic therapy in unstable angina is currently unknown, despite the pathogenetic similarity of this entity to acute myocardial infarction, for which thrombolysis has enjoyed great success. To compare the clinical benefit of intravenous urokinase with that of conventional antithrombotic therapy in preventing the progression of unstable angina to new myocardial infarction, intractable angina, or death within the first 96 hours after hospitalization, 149 patients with unstable angina were randomized to one of two intravenous thrombolytic strategies. METHODS AND RESULTS. Forty-nine patients received 3 million units urokinase i.v. over 90 minutes plus intravenous heparin (group A); 47 patients received unblinded 3 million units urokinase i.v. plus 325 mg aspirin p.o. daily (group B); and 53 patients received placebo thrombolytic infusion plus full-dose heparin (group C). The primary end point of this trial was 96-hour clinical status. There were no significant differences in the baseline characteristics (age, sex, previous myocardial infarction, hypertension prevalence, diabetes, tobacco use, or previous revascularization) among the three groups. Despite an excess of minor untoward reactions for the urokinase groups (chills, 26.5% and 23.4% for groups A and B versus 0% for group C; p < 0.01), there was no significant difference with respect to major bleeds (two, none, and two for groups A, B, and C, respectively; p = NS). At 96 hours after presentation, no significant difference emerged in the incidence of new cardiac events: new myocardial infarctions developed in 10.2% of group A, 6.4% of group B, and 3.8% of group C (p = NS); intractable angina occurred in 6.1% of group A, 10.6% of group B, and 9.4% of group C (p = NS). There were no deaths. All three groups encountered a similar incidence of overall cardiac events: 16.3%, 17.0%, and 13.2% for groups A, B, and C, respectively (p = NS). Although trial enrollment was to extend to 600 patients, interim analysis led to early cessation of enrollment due to a negative trend in respect to outcome after thrombolysis. CONCLUSIONS. High-dose intravenous urokinase followed by either heparin or aspirin can be safely administered to a broad, unselected group of patients with unstable angina. However, this study suggests that no clinical advantage is conferred by urokinase, with either adjunctive antithrombotic therapy over standard heparin therapy alone, when given relatively late (mean, 8.7 hours) after admission for unstable angina. A possible detrimental effect cannot be excluded.     

Comparison of Results of Coronary Angioplasty in Patients with Unstable vs. Stable Angina

Objectives To compare the short and mid - term outcomes in cases of percutaneous transluminal coronary angioplasty (PTCA) in patients with unstable v stable angina. Methods Patients selected for PTCA/stenting were divided in to two groups, one with stable angina pectoris (SA group, n = 92) and one with unstable angina pectoris (UA group, n = 112). The outcomes of coronary an giographies (CAG), initial (30-d) success of the procedure, and follow - up status in the two groups were compared. Results Baseline characteristics were similar, although the patients with unstable symptoms more females ( P< 0. 05), and had a higher average CCS class (P< 0. 05) and a higher incidence of postinfarction angina ( P< 0. 01). The frequency of ' complex stenosis in patients with unstable angina was higher than that of patients with stable angina, 33% v 20% ( P< 0. 01). A total of 309 vessels ac cepted the procedure; including 210 stents were sue cessfully delivered to 156 patients. 143 and 67 stents were implanted in the     

不稳定型与稳定型心绞痛冠状动脉成形术的比较

目的　比较不稳定型心绞痛 (UA)与稳定型心绞痛 (SA)患者接受冠状动脉成形术 (PTCA)的疗效。方法　行PTCA的心绞痛患者 2 0 4例 ,分组比较UA与SA患者冠状动脉造影结果及PTCA术的近期和中期疗效。结果　①分组 :2 0 4例病人中 ,UA组 112例 (5 5 % ) ,SA组 92例 (45 % )。其中UA组心绞痛分级高于SA组 (P <0 0 5 )。②UA组复杂病变血管支数为 74(3 3 % ) ,SA组复杂病变血管 43支(2 0 % ) ,两组比较差异显著 (P <0 0 1) ;而SA组多支血管病变的发生较UA组为多 (P <0 0 5 )。③支架植入情况 :UA组有 114支血管共植入支架 143枚 ,占病变血管数的 5 1% ;SA组 5 4支血管共 67枚 ,占 2 5 % ,两组比较差异显著 (P <0 0 1) ,共 15 6例病人接受支架术。④术后 3 0d内无重大并发症发生 ,UA组复发胸痛较SA组高 (9%vs 3 % ,P <0 0 5 )。⑤随访 3～ 9个月 ,发生心肌梗死 3例 ,其中UA患者2例。复发胸痛两组分别为 12例和 16例 ,占 13 %和 14% ;临床再狭窄发生率分别为 2 0 %和 2 2 % ,均无显著差别。结论　PTCA/支架术对不稳定型与稳定型心绞痛患者的疗效相似 ,即刻成功率高 ,中期疗效满意